Blood Cancer Diagnostics Market Highlights Various Opportunities 2017-2022 End
The research was carried out at Harvard Medical School and Massachusetts General Hospital Cancer Center. Inclusion of liquid biopsy can help in identifying resistance alternations in patients with advanced cholangiocarcinoma.
[UKPRwire, Fri Sep 06 2019] Fact.MR, in its recent research, offers market forecast and analysis on the blood cancer diagnostics market for the period, 2017-2022. According to the research, the global blood cancer diagnostics market is projected to grow at 6.4% CAGR through 2022. The key takeaways from Fact.MR’s research report include,
By test type, the CBC segment, which is currently valued at nearly US$ 77 million, is projected to grow at nearly 5% CAGR. In the North America blood cancer diagnostics market, these tests will continue to account for a significant share of overall revenues.
Owing to highly accurate diagnosis, blood testing will also continue to be a widely used test globally. Fact.MR projects this segment to rake in significant revenues by 2022.
Request for Sample Report with Statistical info @ https://www.factmr.com/connectus/sample?flag=S&rep_id=47
On back of recent reports about the accuracy and benefits of using liquid biopsy, this segment is gaining traction globally. Research carried out at Massachusetts General Hospital Cancer Center and Harvard Medical School has shown that liquid biopsy can help patients with advanced cholangiocarcinoma. Fact.MR projects this segment to grow at a high CAGR through 2022.
The bone marrow test type is also being widely used by end-users owing to its efficacy in diagnosis and management. According to Fact.MR’s analysis, the bone marrow test type is anticipated to rake in significant revenues during the forecast period. Revenues from this segment are anticipated to grow at a healthy CAGR through 2022.
Hospital associated labs account for a significant revenue share of the overall demand for blood cancer diagnostics. According to Fact.MR’s analysis, this end-use segment is projected to grow at over 6% CAGR through 2022.
Independent diagnostic laboratories are also a major end-user of blood cancer diagnostics. Fact.MR estimates revenues from this segment to grow at over 6% CAGR through 2022. Demand is also anticipated to be strong from the cancer research institutes segment.
The blood cancer diagnostics market in the U.S. will continue to account for a significant share of the global revenues. The U.S. will also remain significant owing to R&D and new developments in diagnostics. Fact.MR projects the U.S. blood cancer diagnostics market to account for leading revenue share of the global market.
In Europe, Germany and U.K. will account for significant revenue share of the global revenues. Advancements in R&D, combined with increasing prevalence of the disease will hamper growth of the market.
Leading companies in the market are focusing on investing in R&D to come up with innovative and accurate diagnostics solutions. Mergers and acquisitions, and collaborations will continue to remain a trend in this market.
Need more Information about Report Methodology @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=47
The report has also profiled key players in the global market for blood cancer diagnostics, which include companies such as Abbott Laboratories, Thermo Fisher Scientific Inc., Roche Holding A.G., Laboratory Corporation of America Holdings, Luminex Corporation, NanoString Technologies Inc, Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Quest Diagnostics Incorporated, Siemens AG, Qiagen N.V., Biotheranostics, Inc, Agilent Technologies, Almac Group Limited, and GeneNews Limited.